SR9009
CAS No. 1379686-30-2
SR9009 ( SR9009 | SR 9009 | SR-9009 | Stenabolic )
产品货号. M17268 CAS No. 1379686-30-2
SR9009 是一种 REV-ERB 激动剂,可增加 REV-ERBα/ERBβ 调节的基因的组成型抑制(IC50:670/800 nM)。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 2MG | ¥316 | 有现货 |
|
| 5MG | ¥568 | 有现货 |
|
| 10MG | ¥800 | 有现货 |
|
| 25MG | ¥1218 | 有现货 |
|
| 50MG | ¥2251 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
| 1 mL x 10 mM in DMSO | ¥682 | 有现货 |
|
生物学信息
-
产品名称SR9009
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述SR9009 是一种 REV-ERB 激动剂,可增加 REV-ERBα/ERBβ 调节的基因的组成型抑制(IC50:670/800 nM)。
-
产品描述SR9009, a REV-ERB agonist, increases the constitutive repression of genes regulated by REV-ERBα/ERBβ (IC50: 670/800 nM). Through activation of REV-ERB, SR9009 can decrease circadian locomotor activity during the dark phase and alter the expression pattern of core clock genes in the hypothalami of mice.?The circadian pattern of expression of an array of metabolic genes in the liver, skeletal muscle, and adipose tissue was also altered in mice exposed to SR9009, resulting in increased energy expenditure.?In Diet-induced obese mice, SR9009 (100 mg/kg, i.p., b.i.d., for 30 days) could decrease fat mass and markedly improve dyslipidemia and hyperglycemia.(In Vitro):SR9009 dose-dependently increases the REV-ERB-dependent repressor activity assessed in HEK293 cells expressing a chimeric Gal4 DNA Binding Domain (DBD)-REV-ERB ligand binding domain (LBD)α or β and a Gal4-responsive luciferase reporter (SR9009: REV-ERBα IC50=670 nM, REV-ERBβ IC50=800 nM). SR9009 potently and efficaciously suppresses transcription in a cotransfection assay using full-length REV-ERBα along with a luciferase reporter driven by the Bmal1 promoter (IC50=710 nM). SR9009 suppresses the expression of BMAL1 mRNA in HepG2 cells in a REV-ERBα/β-dependent manner. Direct binding of the SR9009 to REV-ERBα is also confirmed using circular dichrosim analysis (Kd=800 nM). (In Vivo):While the stress of handling and twice-daily injections caused weight loss in vehicle-treated controls, weight loss of SR9009-treated animals is 60% greater. SR9009 (100 mg/kg ,i.p.) treated mice exhibit a more severe reduction in adiposity. Plasma non-esterified fatty acids (NEFA) are also reduced (23%) along with plasma glucose (19%) in the SR9009 treated animals. In the white adipose tissue (WAT) , SR9009 treatment results in a decrease in expression of genes encoding enzymes involved in triglyceride (TG) synthesis as is also observed in lean mice.
-
体外实验——
-
体内实验——
-
同义词SR9009 | SR 9009 | SR-9009 | Stenabolic
-
通路Metabolic Enzyme/Protease
-
靶点Retinoid Receptor
-
受体Rev-ErbBα| Rev-ErbBβ
-
研究领域Others-Field
-
适应症——
化学信息
-
CAS Number1379686-30-2
-
分子量437.94
-
分子式C20H24ClN3O4S
-
纯度>98% (HPLC)
-
溶解度DMSO : ≥ 30 mg/mL 68.50 mM; H2O : < 0.1 mg/mL
-
SMILESCCOC(=O)N1CCC(C1)CN(Cc1ccc(cc1)Cl)Cc1ccc(s1)[N+](=O)[O-]
-
化学全称ethyl 3-[[(4-chlorophenyl)methyl-[(5-nitrothiophen-2-yl)methyl]amino]methyl]pyrrolidine-1-carboxylate
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Solt LA, et al. Nature. 2012 Mar 29;485(7396):62-8.
021-51111890
购物车()
sales@molnova.cn

